Publications by authors named "Carol J Raport"
Article Synopsis
- ALD403 is a monoclonal antibody designed to inhibit CGRP, showing potential as a migraine preventive treatment with a good safety profile.
- The drug was developed by modifying rabbit antibodies to prevent unwanted immune reactions, and it effectively blocks CGRP-induced actions in lab tests.
- ALD403 did not trigger immune cell destruction mechanisms and demonstrated strong efficacy in animal studies by reducing blood flow response linked to pain, highlighting its potential for migraine management.
Chemokines play a key role in leukocyte recruitment during inflammation and are implicated in the pathogenesis of a number of autoimmune diseases. As such, inhibiting chemokine signaling has been of keen interest for the development of therapeutic agents. This endeavor, however, has been hampered due to complexities in the chemokine system.
View Article and Find Full Text PDF